{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Medical Instruments & Supplies news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/medical-instruments-supplies/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/medical-instruments-supplies/feed.json", "description": "Latest Medical Instruments & Supplies company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:7a92c6b19227f993f9d52ad3ce521cc34e10bddf97df9b2d301ee4f7b1588245", "url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "external_url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "title": "SOLV Plans Health Information Systems Business Spinoff to Drive Growth", "content_text": "Solventum SOLV plans to separate its Health Information Systems (HIS) business as part of its portfolio optimization strategy. The move is expected to sharpen the company's focus on its core MedSurg and Dental Solutions businesses while allowing HIS to pursue its growth opportunities as a standalone entity. From an investor perspective, the planned separation could unlock shareholder value by creating a more focused MedTech business and enabling targeted capital allocation toward Solventum's higher-priority growth areas. HIS, which generates $1.4 billion in annual sales and serves more than 75", "date_published": "2026-08-14T15:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SOLV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "SOLVENTUM CORP", "sentiment_url": "https://sharemaestro.com/sentiment/9d43f9f9-d4d6-4fd6-8aa2-6958bab1561b/"}]}}, {"id": "source:928823bcde70bb7367b7a01d4b7cf5f0da09d639dff31e4c00c60b5634135b1b", "url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "title": "HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates", "content_text": "HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this medical technology company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. HeartFlow, which belongs to th", "date_published": "2026-08-13T21:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "external_url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026. Per management, the SuperFlex system represents a significan", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:36f6ed0610f17ab8c61df9722e382060654627cc26f4a2cbaacc208156886924", "url": "https://finance.yahoo.com/healthcare/articles/bd-bdx-q3-2026-earnings-122827670.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bd-bdx-q3-2026-earnings-122827670.html", "title": "BD (BDX) Q3 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Shawn Bevec Chairman, Chief Executive Officer and President - Tom Polen Executive Vice President and Chief Financial Officer - Vitor Roque Full Conference Call Transcript Operator: Hello, and welcome to BD's Third Fiscal Quarter 2026 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 688-9445 for domestic calls and area code +1 402-220-1", "date_published": "2026-08-13T12:28:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BDX", "name": "Becton, Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/ea5c3141-6554-4729-876f-fabf636b12e0/"}]}}, {"id": "source:f5779e4d294a5d68ac90e5e2f8d997eb9bf426b8297f0edeea8d0e8cb1959134", "url": "https://finance.yahoo.com/markets/stocks/articles/staar-surgical-staa-surpasses-q2-211002195.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/staar-surgical-staa-surpasses-q2-211002195.html", "title": "Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates", "content_text": "Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +47.62%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0.13 per share when it actually produced earnings of $0.38, delivering a surprise of +192.31%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Staar Surgical,", "date_published": "2026-08-12T21:10:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:994884ad159881682eed991e1e25206c3bf95661824968f529358532db52d15d", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-add-brightspring-stock-154100785.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heres-why-add-brightspring-stock-154100785.html", "title": "Here's Why You Should Add BrightSpring Stock to Your Portfolio Now", "content_text": "BrightSpring Health Services, Inc. BTSG is well-poised for growth in the coming quarters, backed by strong momentum in Provider Services, expanding specialty and infusion operations, successful integration of acquired home health assets and a scalable home-based care platform. However, the Inflation Reduction Act (IRA)-related reimbursement pressure, brand-to-generic conversion headwinds and customer exits in Home and Community Pharmacy could create uneven growth trends and weigh on near-term margin realization through 2026. This Zacks Rank #1 (Strong Buy) company's shares have rallied 54.6% i", "date_published": "2026-08-12T15:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:2811532d7a8577576cfceab76f423ba62c11efd9b352e736640b5f1c8791702a", "url": "https://finance.yahoo.com/healthcare/articles/npce-q2-earnings-beat-estimates-152200716.html", "external_url": "https://finance.yahoo.com/healthcare/articles/npce-q2-earnings-beat-estimates-152200716.html", "title": "NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up", "content_text": "NeuroPace, Inc. NPCE reported a second-quarter 2026 loss per share of 18 cents, compared with a loss of 30 cents in the year-ago period. The figure beat the Zacks Consensus Estimate by 5.3%. Shares of NPCE were down approximately 2.3% during after-market trading following the second-quarter results. The company's shares have lost 2.6% in the year-to-date period compared with the industry's decline of 5.9%. However, the broader S&P 500 Index has increased 12.5% in the same time frame.Zacks Investment Research Image Source: Zacks Investment Research NPCE's Q2 Revenues Show Core Momentum NeuroPac", "date_published": "2026-08-12T15:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:b0259a224d0109f83881d0016c1981c58205f0f8dc852f77da3bc09682efd352", "url": "https://www.nasdaq.com/articles/intuitive-surgical-isrg-stock-has-plunged-33-2026-heres-why-one-fund-manager-remains", "external_url": "https://www.nasdaq.com/articles/intuitive-surgical-isrg-stock-has-plunged-33-2026-heres-why-one-fund-manager-remains", "title": "Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too.", "content_text": "Key Points The robotic surgery specialist has over 12,000 installed systems globally. Right now, it's facing some headwinds, but it also has a lot going for it. The Baron Health Care Fund sees Intuitive Surgical as full of promise.10 stocks we like better than Intuitive Surgical \u203a If you're not familiar with Intuitive Surgical(NASDAQ: ISRG), know this: It's a massive robotic surgical systems specialist, with a recent market value topping $135 billion. That market value was quite a bit higher not so long ago, though -- because while the stock has averaged annual gains of 17% over the past decad", "date_published": "2026-08-12T13:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:0f730957215724fed72c0676028ca481b671a1c667c1d0f654137bf7849ad1c6", "url": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-intuitive-surgical-inc-123002658.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invested-1000-intuitive-surgical-inc-123002658.html", "title": "If You Invested $1000 in Intuitive Surgical, Inc. 10 Years Ago, This Is How Much You'd Have Now", "content_text": "For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks. What if you'd invested in Intuitive Surgical, Inc. (ISRG) ten years ago? It may not have been easy to hold on to ISRG for all that time, but if you did, how much would your investment be worth today? Intuitive Surgical, Inc.'s Business In-Depth ", "date_published": "2026-08-12T12:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:f9934b85d4d07a07af4b86760fb38b6cf174ed6a2960e42925eb1492a00e8735", "url": "https://finance.yahoo.com/healthcare/articles/cah-q4-earnings-beat-pharma-162100894.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cah-q4-earnings-beat-pharma-162100894.html", "title": "CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up", "content_text": "Cardinal Health, Inc. CAH reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.91, beating the Zacks Consensus Estimate by 20.3%. The bottom line improved 40% year over year, aided by higher operating earnings, IEEPA tariff refunds, a lower tax rate and a reduced share count. GAAP EPS in the quarter was $1.70 compared with $1.00 in the year-ago period. Full-year fiscal 2026 adjusted EPS was $11.26, up 37% compared to the figure at the end of the fiscal 2025 period. The company reported GAAP EPS of $7.23 in fiscal 2026, compared with $6.45 in the year-ago period. Q4 Reven", "date_published": "2026-08-11T16:21:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:e85346ffd0edee02a16650e1a6c76dbca5fb4845efef5deb86f81740296a0276", "url": "https://finance.yahoo.com/healthcare/articles/rdnt-q2-earnings-sales-beat-152000898.html", "external_url": "https://finance.yahoo.com/healthcare/articles/rdnt-q2-earnings-sales-beat-152000898.html", "title": "RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised", "content_text": "RadNet, Inc. RDNT reported second-quarter 2026 adjusted earnings of 29 cents per share, down 14.7% year over year but ahead of the Zacks Consensus Estimate of 18 cents by 61.1%. GAAP EPS was 10 cents compared with 19 cents in the prior-year period. Growth was led by stronger advanced imaging volumes, recent acquisitions and Digital Health expansion. Annual recurring revenues, or ARR, in Digital Health reached $105.5 million, up 97% year over year. Revenue Details Revenues rose 25% to $622.7 million, topping the consensus mark by 1.4%. RadNet's share price improvement of 8.3% so far this year h", "date_published": "2026-08-11T15:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:e804185921e0d0bea9267ff733faf84742d1a9c3526419fca8aeb6a64a26d14e", "url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-cah-q4-earnings-115502270.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/cardinal-health-cah-q4-earnings-115502270.html", "title": "Cardinal Health (CAH) Q4 Earnings Beat Estimates", "content_text": "Cardinal Health (CAH) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.42 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +20.25%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $2.8 per share when it actually produced earnings of $3.17, delivering a surprise of +13.21%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Cardinal, whic", "date_published": "2026-08-11T11:55:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:6a72a8cb7db1d804268e52713bf361ab6033dc12c50d8ad41de82dd031abfd60", "url": "https://finance.yahoo.com/healthcare/articles/solv-q2-deep-dive-portfolio-094122852.html", "external_url": "https://finance.yahoo.com/healthcare/articles/solv-q2-deep-dive-portfolio-094122852.html", "title": "SOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape Outlook", "content_text": "SOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape Outlook Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts' consensus estimates. Is now the time to buy SOLV? Find out in our full research report (it's free). Solventum (SOLV) Q2 CY2026 Highlights: Revenue: $2.21 billion vs analyst estimates of $2.15 billion (2.2% year-on-year growth, 2.5% beat) Adjusted EPS: $2.55 vs analyst estimates of $1.91 (3", "date_published": "2026-08-11T09:41:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SOLV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "SOLVENTUM CORP", "sentiment_url": "https://sharemaestro.com/sentiment/9d43f9f9-d4d6-4fd6-8aa2-6958bab1561b/"}]}}, {"id": "source:d06400357bb479d51ff975abb5cf2273427affbbac71e718f8d70d26d552f538", "url": "https://seekingalpha.com/news/4630376-bionano-outlines-31m-33m-2026-revenue-forecast-amid-flow-cell-supply-constraints?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4630376-bionano-outlines-31m-33m-2026-revenue-forecast-amid-flow-cell-supply-constraints?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Bionano outlines $31M-$33M 2026 revenue forecast amid flow cell supply constraints", "content_text": "Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * \"Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers,\" said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding that \"the growth of our consumable sales this quarter was primarily driven by increased clinical adoption\" and that management expects clinical adoption and utilization \"to remain the foundation of our growth.\" * \"We're pleased to welcome back Dr. Alex Hastie as our Chief Scientific Officer,\"", "date_published": "2026-08-10T22:39:09+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "BNGO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BNGO", "name": "Bionano Genomics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1417783f-4f97-4e9a-a77a-907238a4185b/"}]}}, {"id": "source:5e24f116e94ed703b1d3d5525dad9a6595c1e7a17622c24056a09e8b6634a74d", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-just-beat-210447165.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-just-beat-210447165.html", "title": "Intuitive Surgical (ISRG) Just Beat Earnings. Is the Stock Still Worth Paying a Premium?", "content_text": "Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS of $2.80 exceeding expectations by $0.30. Despite that, the stock plunged due to mounting concerns about slowing domestic procedure growth. Worldwide procedures, da Vinci and Ion combined, grew around 16% compared to the prior year period, with Da Vinci procedures growing approximately 15% and Ion procedures growing approximately 36%. These trends disappointed investors accustomed to the company's historica", "date_published": "2026-08-10T21:04:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:08c9d497cf0aee142a5c3ddda70974c45a185d7285f81b15caf609773800d60e", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxOTDNDVndrZjhGRjFSSUZlc1RNM2hGWDJhWU1qbXFrMDFCSzcwRmJWWkxMdjNKLTcwQVlhQmpwRThsN25XMHhLR3F2TTBQazgycmNkVWtoM05ZeTdCSnlqMC13MDhwdVNIQU9VblZ6aXUzMFdjRVMwX3Jua2h6RzlCYmZRWHAyeFJoa2dHQkhxQ2F0dWxZMlFZdE53UmJWWnF4YlUzb0J0Y2NNaDZNUHBQaFM4X0hSdWY3cmpPQUZ6d0JacG11Y1c4NHRoUnJEclN0R0pIVVhjcHBpWFEwdlJBZTBvM016SFVHWXc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxOTDNDVndrZjhGRjFSSUZlc1RNM2hGWDJhWU1qbXFrMDFCSzcwRmJWWkxMdjNKLTcwQVlhQmpwRThsN25XMHhLR3F2TTBQazgycmNkVWtoM05ZeTdCSnlqMC13MDhwdVNIQU9VblZ6aXUzMFdjRVMwX3Jua2h6RzlCYmZRWHAyeFJoa2dHQkhxQ2F0dWxZMlFZdE53UmJWWnF4YlUzb0J0Y2NNaDZNUHBQaFM4X0hSdWY3cmpPQUZ6d0JacG11Y1c4NHRoUnJEclN0R0pIVVhjcHBpWFEwdlJBZTBvM016SFVHWXc?oc=5", "title": "Bionano Genomics presenta sus previsiones de ingresos para el tercer trimestre y el ejercicio 2026", "content_text": "Bionano Genomics presenta sus previsiones de ingresos para el tercer trimestre y el ejercicio 2026", "date_published": "2026-08-10T20:05:00+00:00", "authors": [{"name": "es.marketscreener.com"}], "tags": ["Market update", "BNGO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BNGO", "name": "Bionano Genomics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1417783f-4f97-4e9a-a77a-907238a4185b/"}]}}, {"id": "source:41c92cab4ed8e228545e082a0cd11628d94fc82e3e905d6caa827d052eed5bbd", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-sees-cheap-valuation-175313326.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-sees-cheap-valuation-175313326.html", "title": "Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance", "content_text": "On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC's Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That's the big medical technology and supply play... That was formerly known as Becton, Dickson. This was the first full quarter after they split off their biosciences and diagnostics business, something we loved. They posted a 9-cent earnings beat off a $3.14 basis, higher-than-expected revenue, up 5.4% year-over-year. They also said their full-year revenue growth would be toward ", "date_published": "2026-08-10T17:53:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "BDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BDX", "name": "Becton, Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/ea5c3141-6554-4729-876f-fabf636b12e0/"}]}}, {"id": "source:1964518e6aa2f069cdd57129d4b6767ff909309c12af6189d837341efd939e91", "url": "https://finance.yahoo.com/healthcare/articles/inogen-q2-earnings-beat-estimates-165400227.html", "external_url": "https://finance.yahoo.com/healthcare/articles/inogen-q2-earnings-beat-estimates-165400227.html", "title": "Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut", "content_text": "Inogen, Inc. INGN reported breakeven earnings for second-quarter 2026, compared to the year-ago period's adjusted loss of 2 cents per share. GAAP loss per share of 14 cents, narrower than the year-ago loss of 15 cents. The figure beat the Zacks Consensus Estimate by 17.7%. Year to date, the company's shares have lost 10% compared with the industry's fall of 8.5%. However, the S&P 500 Index has increased 13.1% in the same time frame.Zacks Investment Research Image Source: Zacks Investment Research INGN's Q2 Revenues in Detail Inogen registered revenues of $95.1 million for the second quarter of", "date_published": "2026-08-10T16:54:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:ad71c31961cdb97b4ab95e0cc6a65f4e4ef48905abe2764a6b0b0b9a32519966", "url": "https://finance.yahoo.com/healthcare/articles/irhythm-q2-earnings-beat-estimates-163700520.html", "external_url": "https://finance.yahoo.com/healthcare/articles/irhythm-q2-earnings-beat-estimates-163700520.html", "title": "iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised", "content_text": "iRhythm Holdings, Inc. IRTC reported adjusted earnings per share of 58 cents in the second quarter of 2026, against an adjusted loss per share of 32 cents a year ago. The figure beat the Zacks Consensus Estimate by 5900%. GAAP loss per share for the quarter was 1 cent compared with 44 cents in the year-ago period. IRTC's Q2 Revenues in Detail iRhythm registered revenues of $224.2 million in the second quarter, up 20.1% year over year. The increase was primarily driven by sustained volume demand across the customer base, reflecting continued strength in the core business and contributions from ", "date_published": "2026-08-10T16:37:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:b34e1af58234f6b7dfa4cba07d4f7c14f25e85cad001b777845b73e7830cf0f0", "url": "https://seekingalpha.com/news/4629639-earnings-week-ahead-smci-csco-jd-plug-and-more?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629639-earnings-week-ahead-smci-csco-jd-plug-and-more?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more", "content_text": "[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consumer names, with Super Micro Computer (SMCI [https://seekingalpha.com/symbol/SMCI]), Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Cisco Systems (CSCO [https://seekingalpha.com/symbol/CSCO]), CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]), and Lumentum (LITE [https://seekingalpha.", "date_published": "2026-08-09T12:07:00+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "BNGO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BNGO", "name": "Bionano Genomics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1417783f-4f97-4e9a-a77a-907238a4185b/"}]}}, {"id": "source:0676c94d4c6b7e384c3dd187245e72d9d7fb7443e3c8472f031b5e396bc65e83", "url": "https://finance.yahoo.com/markets/stocks/articles/solventum-solv-stock-fair-value-080943338.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/solventum-solv-stock-fair-value-080943338.html", "title": "Solventum (SOLV) Stock Fair Value Rises After Q2 And HIS Separation Plans", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Solventum's analyst fair value estimate has been revised from US$82.15 to US$93.15, a shift of about 13% in the updated framework. This adjustment aligns with recent analyst commentary that points to Q2 results, the planned Health Information Systems separation, and views on the company's MedTech focus as reasons to revisit price targets. Read on to see how these factors shape the evolving Solventum narrative and what to watch as new data comes in. Analyst", "date_published": "2026-08-09T08:09:43+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "SOLV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "SOLVENTUM CORP", "sentiment_url": "https://sharemaestro.com/sentiment/9d43f9f9-d4d6-4fd6-8aa2-6958bab1561b/"}]}}, {"id": "source:ba0d67fee27205d645a1b06dcd2e7dd93826039a4894bb643f53aaa14cfc74cf", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-stock-looks-020803082.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-stock-looks-020803082.html", "title": "Intuitive Surgical (ISRG) Stock Looks Fairly Valued Despite Its 33% Slide", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Intuitive Surgical stock has had a difficult start to 2026, with the share price down 32.6% year to date, while the Discounted Cash Flow (DCF) intrinsic value estimate now points to a level that is broadly in line with where the market is pricing the company. The year to date decline of 32.6% raises the question of whether recent weakness is now fully reflected in the share price. Management commentary around durable demand for platforms like da Vinci 5 ", "date_published": "2026-08-09T02:08:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:d4bf15b2230cbd7b388ab35f957cf11c1c7f0b4d4233cedd8aa0b69c8eb232a6", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-bylaw-changes-011205591.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-bylaw-changes-011205591.html", "title": "What Do Intuitive Surgical (ISRG) Bylaw Changes Mean For Shareholders?", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Intuitive Surgical (NasdaqGS: ISRG) has approved amendments to its bylaws, updating shareholder voting rules, nomination processes, and procedural requirements in line with recent SEC universal proxy regulations. The revised bylaws clarify how proxy solicitations are conducted and what shareholders must disclose when putting forward director nominees or other proposals. The changes affect how investors can engage with the company on governance matters and may influence future proxy conte", "date_published": "2026-08-09T01:12:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:ef97591fe7287717984e55a5dbfd4afdc7056c911aa271ab0319d5876ea6e60b", "url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "external_url": "https://finance.yahoo.com/healthcare/articles/robotic-surgery-leader-intuitive-surgical-110549493.html", "title": "The Robotic Surgery Leader: Intuitive Surgical Slides Further But One Wall Street Bull Pegs Returns at 85%", "content_text": "Quick Read ISRG dropped 34% on a slower procedure growth guide, yet Q2 EPS of $2.80 crushed the $2.50 consensus for a fifth straight quarterly beat. ISRG trades 28% below Wall Street consensus while peers MDT and SYK fell less than 10% YTD, suggesting the market overcorrected on the category leader. Bernstein's $685 target implies 83% upside with the bull case hinging on the da Vinci 5 upgrade cycle mirroring the prior seven-year Xi ramp. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Intuitive Surgical didn't make the cut. Grab the names FREE today. Intui", "date_published": "2026-08-08T11:05:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ISRG"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1e25b596-ff41-4c0e-b3d3-2f71b279e663/"}]}}, {"id": "source:4c553a6e8a7072b0539768d73b7a3622168da24bcde7639b9e82c796a63d2c08", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1iSzdFS080UWYxd0EyTVZ4Qm9VZ3R6WUtTZEd6c3NzZGVwbjRRZzR2RlRMUFlSTGFuZFFYQWszTl9FSUlXd1RzMTMxd1FfSmVDdlJMRG00VEhCSEFYaF83bDFlR3o?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE1iSzdFS080UWYxd0EyTVZ4Qm9VZ3R6WUtTZEd6c3NzZGVwbjRRZzR2RlRMUFlSTGFuZFFYQWszTl9FSUlXd1RzMTMxd1FfSmVDdlJMRG00VEhCSEFYaF83bDFlR3o?oc=5", "title": "Noticias de acciones de Solventum Corp (SOLV)", "content_text": "Noticias de acciones de Solventum Corp (SOLV)", "date_published": "2026-08-08T08:22:43+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "SOLV"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "SOLVENTUM CORP", "sentiment_url": "https://sharemaestro.com/sentiment/9d43f9f9-d4d6-4fd6-8aa2-6958bab1561b/"}]}}, {"id": "source:d0eec9991b44c3f882a0f53a752ec4e7ae877fa8518a6c1b6fddea0e4633444a", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5UWTA0bDZWdmFOQTVMTWE5NlhNTkJERDVPRi03WS1rYjZ5OUNZNWdMTkI5dmk3RGZCWjBNMFgzUWgxdUFDMi1XSktsRkVLdE81UVpreGlvbkZEZURYY1VNa3hLWFU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5UWTA0bDZWdmFOQTVMTWE5NlhNTkJERDVPRi03WS1rYjZ5OUNZNWdMTkI5dmk3RGZCWjBNMFgzUWgxdUFDMi1XSktsRkVLdE81UVpreGlvbkZEZURYY1VNa3hLWFU?oc=5", "title": "Noticias de acciones de Bionano Genomics Inc (BNGO)", "content_text": "Noticias de acciones de Bionano Genomics Inc (BNGO)", "date_published": "2026-08-08T05:48:58+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "BNGO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BNGO", "name": "Bionano Genomics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1417783f-4f97-4e9a-a77a-907238a4185b/"}]}}, {"id": "source:3f06f522806ff27616195570e12dea997b75debc4e2f7f1715b10b2c12e98530", "url": "https://finance.yahoo.com/healthcare/articles/becton-dickinson-co-bdx-q3-030409755.html", "external_url": "https://finance.yahoo.com/healthcare/articles/becton-dickinson-co-bdx-q3-030409755.html", "title": "Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...", "content_text": "This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. Free Cash Flow: $1.7 billion year to date, an increase of 45% versus the prior year. Segment Performance: Medical Essentials grew 3.2%, Connected Care grew 4.4%, BioPharma Systems grew 5.2%, and Interventional grew 5.5%. Guidance: Full-year revenue growth expected toward the high end of the low single-digit FX-neutral r", "date_published": "2026-08-08T03:04:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BDX", "name": "Becton, Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/ea5c3141-6554-4729-876f-fabf636b12e0/"}]}}, {"id": "source:801b4cc66c4dfd394167176c8248c4eb4022a734dd8ae6e45e7b33003485e71d", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE04emc3bFZhcHZKTVJJenhpaHNjNDhYVGF1YjBQZzZOTEhyWXYzbWpNRWNhZGNtMkJzNDNSZTQ3a05KTU5IZmtqaE44TDlCeW4xSVdhc3ZBazJrVE80SDlhc0xzRQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE04emc3bFZhcHZKTVJJenhpaHNjNDhYVGF1YjBQZzZOTEhyWXYzbWpNRWNhZGNtMkJzNDNSZTQ3a05KTU5IZmtqaE44TDlCeW4xSVdhc3ZBazJrVE80SDlhc0xzRQ?oc=5", "title": "Noticias de acciones de Cooper Companies Inc (COO)", "content_text": "Noticias de acciones de Cooper Companies Inc (COO)", "date_published": "2026-08-07T20:31:17+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}, {"id": "source:33bffe5cf3b268d045c28d9a4c80472ffa5e6f27e9f6fed1d063bb2bc4b1c26f", "url": "https://finance.yahoo.com/markets/stocks/articles/xray-stock-falls-despite-q2-183500633.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/xray-stock-falls-despite-q2-183500633.html", "title": "XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales", "content_text": "DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 cents against loss per share of 22 cents in the prior-year quarter. XRAY's Revenue Trends and Regional Mix Revenues declined 4.1% reportedly to $898 million and 6.3% at constant currency (cc). The metric, however, beat the Zacks Consensus Estimate by 1.6%. Weakness across three dental segments weighed on sales, partly offset by Wellspect Heal", "date_published": "2026-08-07T18:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/031d48eb-0b93-46b1-9b95-58f6925e7455/"}]}}]}